探究瑞舒伐他汀对冠心病合并高脂血症老年患者血脂水平和炎症因子含量的影响  

Investigation on effect of rosuvastatin on serum lipids levels and inflammatory factors content in elderly patients with coronary heart disease and hyperlipidemia

作　　者：朱可云 ZHU Ke-yun(Xinhui District People’s Hospital,Jiangmen 529100,China)

机构地区：[1]新会区人民医院,529100

出　　处：《中国实用医药》2020年第5期102-104,共3页China Practical Medicine

摘　　要：目的探究瑞舒伐他汀对冠心病合并高脂血症老年患者血脂水平和炎症因子含量的影响。方法90例冠心病合并高脂血症老年患者,根据信封法随机分成瑞舒伐他汀组和阿托伐他汀组,每组45例。阿托伐他汀组给予阿托伐他汀治疗,瑞舒伐他汀组则给予瑞舒伐他汀治疗。比较两组疾病好转情况、治疗前后血脂和炎症因子水平、血脂控制良好的时间、异常心电图纠正的时间、不良反应发生情况。结果瑞舒伐他汀组疾病好转率97.78%高于阿托伐他汀组的71.11%,差异具有统计学意义(P<0.05)。治疗后,瑞舒伐他汀组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、白介素-6(IL-6)、白介素-8(IL-8)水平分别为(3.12±0.23)mmol/L、(2.55±0.12)mmol/L、(1.32±0.11)mmol/L、(60.10±2.11)pg/ml、(160.25±6.22)pg/ml均优于阿托伐他汀组的(3.52±0.15)mmol/L、(3.62±0.24)mmol/L、(1.87±0.20)mmol/L、(124.45±2.41)pg/ml、(211.98±14.02)pg/ml,差异具有统计学意义(P<0.05)。瑞舒伐他汀组血脂控制良好的时间(10.11±1.41)d、异常心电图纠正的时间(3.13±0.21)d均短于阿托伐他汀组的(14.42±2.25)、(5.23±1.21)d,差异具有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论瑞舒伐他汀治疗冠心病合并高脂血症老年患者的疗效确切,可有效降低血脂水平和炎症因子含量,有效改善心功能,缩短治疗的时间,且无明显不良反应,值得推广应用。Objective To investigate the effect of rosuvastatin on serum lipids levels and inflammatory factors content in elderly patients with coronary heart disease and hyperlipidemia.Methods A total of 90 elderly patients with coronary heart disease and hyperlipidemia were divided into rosuvastatin group and atorvastatin group by envelope method,with 45 cases in each group.Atorvastatin group was treated by atorvastatin,and rosuvastatin group was treated by rosuvastatin.The improvement of disease,the levels of serum lipid and inflammatory factors,the time of good serum lipid control,the correction time of abnormal electrocardiogram and the occurrence of adverse reactions were compared between the two groups.Results The improvement rate of disease 97.78%in rosuvastatin group was higher than 71.11%in atorvastatin group,and the difference was statistically significant(P<0.05).After treatment,the levels of total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),triglycerides(TG),interleukin-6(IL-6),interleukin-8(IL-8)were(3.12±0.23)mmol/L,(2.55±0.12)mmol/L,(1.32±0.11)mmol/L,(60.10±2.11)pg/ml and(160.25±6.22)pg/ml respectively in rosuvastatin group,which were all better than(3.52±0.15)mmol/L,(3.62±0.24)mmol/L,(1.87±0.20)mmol/L,(124.45±2.41)pg/ml and(211.98±14.02)pg/ml respectively in atorvastatin group,and their difference was statistically significant(P<0.05).Time of good serum lipid control(10.11±1.41)d and correction time of abnormal electrocardiogram(3.13±0.21)d in rosuvastatin group was shorter than(14.42±2.25)and(5.23±1.21)d in atorvastatin group,and their difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of adverse reactions between the two groups(P>0.05).Conclusion Rosuvastatin shows certain efficacy for the treatment of coronary heart disease and hyperlipidemia.It can effectively reduce the level of serum lipid and the content of inflammatory factors,effectively improve the heart function,shorten the treatment time with no obvious adv

关 键 词：瑞舒伐他汀 冠心病合并高脂血症 血脂水平 炎症因子含量 

分 类 号：R541.4[医药卫生—心血管疾病]